Inactive Instrument

Press Releases Sunshine Heart Inc Nasdaq

Equities

US86782U1060

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Nuwellis Announces Pricing of $2.7 Million Public Offering	Apr. 26	AQ
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health	Apr. 09	AQ
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference	Mar. 07	AQ
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results	Mar. 05	AQ
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024	Feb. 27	AQ
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™	Feb. 22	AQ
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 20	AQ
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference	Feb. 20	AQ
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload	Feb. 06	AQ
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter	Jan. 04	AQ
New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients	Nov. 28	AQ
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Nov. 14	AQ
Nuwellis, Inc. Announces Third Quarter 2023 Financial Results	Nov. 07	AQ
Nuwellis Announces Board of Directors Transition	Nov. 01	AQ
Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device	23-10-31	AQ
Nuwellis, Inc. To Announce Third Quarter 2023 Financial Results on November 7, 2023	23-10-18	AQ
Nuwellis Announces Pricing of $2.25 Million Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants	23-10-13	AQ
Nuwellis Provides Regulatory Update on SeaStar Medical’s Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption	23-10-10	AQ
Nuwellis to Present at the Gilmartin Group Emerging Growth Showcase	23-09-11	AQ
Nuwellis, Inc. Announces Second Quarter 2023 Financial Results	23-08-08	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Sunshine Heart Inc Nasdaq

Equities

US86782U1060

Press Releases

Filters